學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Moderna (A)
內容大綱
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital resources to speed its operations, manage its processes and ensure quality across research, testing and manufacturing. Built from the ground up as such a digital organization, Moderna was able to respond to the challenge of developing a vaccine as soon as the gene sequence for the virus was posted to the Web on January 11, 2020. As the vaccine enters Phase III clinical trials, Bancel considers several issues: How should Bancel and his team balance the demands of developing a vaccine for a virus creating a global pandemic alongside the other important vaccines and therapies in Moderna's pipeline? How should Moderna communicate its goals and vision to investors in this unprecedented time? Should Moderna be concerned it will be pegged as "a COVID-19 company?"